Lymphoma Survivor Has First Successful Ovarian Tissue Transplant

Ann Dauer played a major role in a medical advance. Her baby, due in the next few days, will mark the first successful birth after an ovarian tissue transplant in North America and only the second in the world. For the 33-year-old Dauer, the birth brings to a happy end a long journey during which she endured contradictory diagnoses, months of cancer treatment and the uncertainty of whether she and her husband, Greg, would enjoy a family.



Dauer was diagnosed with Hodgkin's lymphoma in early 2001. Doctors talked optimistically about a recovery, but when Dauer was scanned for tumors in January 2002 with the expectation that none would be present, it was clear she was not in remission. The cancer seemed to be growing quickly. Dauer visited Memorial Sloan-Kettering Cancer Center in New York where physicians found that she suffered from a rare combination of Hodgkin's and non-Hodgkin's lymphomas.



The outlook wasn't great. There was a 25 percent chance of beating the condition. The recommended treatment, a stem-cell transplant from cells harvested from her own bone marrow combined with chemotherapy, carried a 10 percent chance of death and would leave her unable to have children. Since she didn't have time for egg harvest, the ovary preservation was the only option.



Read more in the Buffalo News

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap